Skip to main content
Figure 1 | Molecular Pain

Figure 1

From: The role of cation-dependent chloride transporters in neuropathic pain following spinal cord injury

Figure 1

Anti-hyperalgesic effects of bumetanide. A. No difference in locomotor function following SCI in vehicle control and drug treatment groups. Animals were randomly divided into one of two groups (group 1 and 2). Locomotor function was monitored and Basso, Beattie, and Bresnahan (BBB) scores recorded on post-SCI days 2–42 in these groups. BBB scores recovered with time, and reached 13.5–15.7 by day 42 post-SCI. There were no significant differences in BBB scores between group 1 and group 2. B. Effects of Bumetanide on TH. TH was measured and the mean withdrawal latency time (WLT) recorded. Group 1 received vehicle (0.25% NaOH in saline, i.p.) as controls (n = 4) and group 2 received Bumetanide (BU 30 mg/kg, i.p., n = 8). After 1 h of treatment, TH was re-measured and the mean WLT recorded. Data are mean ± SD. * p < 0.05 vs. pre-SCI. # p < 0.05 vs. vehicle.

Back to article page